The Supreme Court of the US has ruled that the abortion pill mifepristone can continue to be prescribed remotely and ...

UK reimbursement authority NICE has recommended that the NHS in England can use AstraZeneca's Imfinzi as the first ...

Cardiac rhythm management is undergoing a significant shift. For decades, cardiac resynchronisation therapy has helped restore synchrony in patients with heart failure and electrical conduction ...

Biogen has decided to advance its tau-targeting Alzheimer's disease drug diranersen (BIIB080) into a phase 3 trial programme, despite a phase 2 trial missing its main efficacy measure. In the 18-month ...

It’s safe to say that AI has firmly captured the interest of decision-makers across the industry. But, as the space continues ...

NHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate hepatitis C from the country - although it has had to drop a 2025 target date because of ...

A California jury has awarded $40 million in damages to two women who sued Johnson & Johnson, claiming that its talc-based Baby Powder product led to their ovarian cancer. The jury in a Los Angeles ...

Bill Gates has made a $50 million donation to the Dementia Discovery Fund, a collaboration between pharma, the UK government and the charity Alzheimer’s Research UK, that aims to challenge the ...

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The EMA's human medicines ...

Roche's Genentech unit has started work on a $700 million manufacturing facility in North Carolina, part of a promised $50 billion investment in the US. The plant – its first on the East Coast of the ...

Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial. Shares in the Anglo-US biotech rose sharply after ...

Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...